İçeriğe geç

Orak Hücre Hastalığı (Çocuk)

Anemi Tedavisi

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (yeni pencere açar)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Kaynak‎: Lancet Haematol. 2023 ;10(4):e261-71.

İndeks‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (yeni pencere açar)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (yeni pencere açar)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Kaynak‎: Acta Haematol 1995;94(3):128-34.

İndeks‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (yeni pencere açar)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (yeni pencere açar)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Kaynak‎: Haematologica 2006;91(8):1076-83.

İndeks‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (yeni pencere açar)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (yeni pencere açar)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Kaynak‎: J Obstet Gynaecol 2007;27(1):82-3.

İndeks‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (yeni pencere açar)